Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANTX
#3609
AN2 Therapeutics, Inc. Common Stock
1.1
0
+1.85%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+1.85%
Monthly Change
-7.56%
6 month change
-3.51%
Year Change
+0.92%
Previous Close
1.0
8
Open
1.1
0
Bid
Ask
Low
1.1
0
High
1.1
0
Volume
1
Markets
US Stock Market
Healthcare
ANTX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Dividends per share
—
—
—
—
Dividend yield %
—
—
—
—
Payout ratio %
—
—
—
—
News
AN2 Therapeutics appoints Sarah Williams as principal accounting officer
FDA clears IND for epetraborole trial in mycobacterium abscessus
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
An2 therapeutics (ANTX): cfo Day sells $8883 in shares
An2 therapeutics CSO prior sells $6507 in stock
Eizen, AN2 Therapeutics COO, sells $25k in ANTX stock
An2 therapeutics chief development officer sells $9k in stock
AN2 Therapeutics partners with GSK to develop TB treatments
Eizen Joshua M of AN2 Therapeutics sells $3213 in stock
Prior Stephen David, AN2 Therapeutics chief strategy officer, sells $872 in stock
AN2 Therapeutics doses first cohort in Phase 1 trial for Chagas disease